The company and one of its subsidiaries would allegedly confuse clinicians and have them bill government programs for cardiac monitoring services that were more expensive than what they needed. This settlement resolves those allegations. 

The Lower Costs, More Transparency Act requires radiologists to publicly list prices for certain "shoppable" services.

“The cardiovascular community has lost an inspiring leader and a man whose warmth and generosity profoundly touched all those who knew him," the European Society of Cardiology said in a statement. 

“We identified a problem in cardiology,” one cardiologist explained. “Heart imaging has made remarkable progress in recent decades, but the electrics of the heart have eluded us."

Ziad Ali, MD, detailed two studies he presented on coronary intravascular lithotripsy at TCT 2023 in San Francisco.

Asian patients are rarely represented in large TAVR trials, the authors wrote, so they focused on nearly 1,200 patients from South Korea to provide a fresh perspective. 

The company's Verafeye platform was designed to provide imaging guidance during cardiac procedures using advanced catheter sensors and deep learning. 

A hybrid approach may increase the risk of certain adverse events, according to a new meta-analysis focused on long-term outcomes. 

Abbott's HeartMate 3 LVAD is the only FDA-approved device of its kind currently available in the United States. Should reports of adverse events worry cardiologists? Or are they to be expected when treating such a vulnerable patient population?

The doctor allegedly targeted some patients more than ten times, treating them again and again with procedures that were not medically necessary.